ArticleCJC open2026
Association Between the Emergency Heart Failure Mortality Risk Grade (EHMRG30-ST) and Costs of Care.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Emergency Heart Failure Mortality Risk Grade (EHMRG30-ST) is a clinically validated model that predicts 30-day mortality in heart failure patients presenting to the emergency department (ED). However, the relationship between the EHMRG30-ST score and costs of care remains unclear. In this study, we explored the relationship between the EHMRG30-ST score and costs of care at 90 and 365 days after the index ED visit, and identified predictors of costs at 90 days. Methods: We combined 2 chart review databases, including 11,407 patients presenting to the ED with heart failure between 2004-2007. We estimated the costs from administrative databases. We stratified patients into quintiles (Q) of EHMRG30-ST scores (Q1 = lowest risk; Q5 = highest risk), and compared the total costs in 2021 Canadian dollars at 90 and 365 days by score quintiles. We further examined the cost breakdown by categories. Finally, we used a generalized linear model to identify predictors of 90-day costs. Results: Patients in the highest EHMRG30-ST risk group (Q5) had higher total costs compared to those for the lowest risk quintile (Q1) at 90 days (CAD$13,453 vs $24,484, Conclusions: Higher mortality risk as determined by the EHMRG30-ST score was associated with higher costs for up to 1 year after the initial ED presentation. Our study suggests that costs of care may be another potential dimension of the utility of prognostic risk scores.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.